RxDoctor Payments Data

Rebecca Levine, MD

Family Medicine · South Jordan, UTNPI 1316986136

Payments from drug & device makers

$1,363in general payments, 2019–2025

Across 72 payments — averaging $18.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$319
  • AstraZeneca$107
  • Pfizer$98
  • Astellas Pharma US Inc$85
  • Axsome Therapeutics, Inc.$68
  • Organon$58
  • plus $628 from 23 others

What the payments were for

  • Food & beverage$1,22890%
  • Education$13510%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,363 in reported general payments places this provider in the 65th percentile of 928 family medicine providers in Utah.

See all family medicine providers in Utah

Medicare billing

Part B allowed, 2024
$30,644
Medicare patients
83
Services billed
364

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide76$84,734
MounjaroTirzepatide42$69,776
EliquisApixaban33$38,148
JanuviaSitagliptin Phosphate42$33,892
JardianceEmpagliflozin15$26,092
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog18$20,987
FarxigaDapagliflozin Propanediol24$18,787
VraylarCariprazine Hcl12$16,670
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$14,527
Lantus SolostarInsulin Glargine,hum.Rec.Anlog62$10,344
Breo ElliptaFluticasone/Vilanterol20$8,903
Celecoxib26$2,874
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate12$2,703
Levothyroxine Sodium222$2,488
Atorvastatin Calcium239$2,439

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$29$84,73476 claims
Lilly USA, LLCMounjaro$35$69,77642 claims
PfizerEliquis$98$38,14833 claims
GSKTrelegy Ellipta, Breo Ellipta$31$23,43033 claims
AstraZenecaFarxiga$107$18,78724 claims
AbbVieVraylar$319$16,67012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 928 family medicine providers in Utah.

Other family medicine in South Jordan

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →